Track topics on Twitter Track topics that are important to you
Regeneron announced phase 3 development of a combination of Eylea and the angiopoietin2 antibody nesvacumab is not warranted after two phase 2 trials failed to show sufficient differentiation, according to a company press release.
The RUBY study, which evaluated patients with diabetic macular edema, and the ONYX study, which evaluated patients with wet age-related macular degeneration, were both randomized, double-masked, active-controlled phase 2 studies that investigated if the combination of Eylea (aflibercept) and nesvacumab would have a benefit over Eylea alone. The combination did not
Original Article: Eylea, nesvacumab combination trials will not continueNEXT ARTICLE
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...
Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...